PlainRecalls
FDA Drug Moderate Class II Ongoing

Rizatriptan Benzoate Tablets USP, 10 mg, 18 (3 X 6) Unit-Dose Tablets, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430 Product of India, NDC 68462-466-99

Reported: June 12, 2024 Initiated: May 10, 2024 #D-0533-2024

Product Description

Rizatriptan Benzoate Tablets USP, 10 mg, 18 (3 X 6) Unit-Dose Tablets, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430 Product of India, NDC 68462-466-99

Reason for Recall

CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.

Details

Units Affected
11,976 cartons
Distribution
US Nationwide.
Location
Mahwah, NJ

Frequently Asked Questions

What product was recalled?
Rizatriptan Benzoate Tablets USP, 10 mg, 18 (3 X 6) Unit-Dose Tablets, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430 Product of India, NDC 68462-466-99. Recalled by Glenmark Pharmaceuticals Inc., USA. Units affected: 11,976 cartons.
Why was this product recalled?
CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.
Which agency issued this recall?
This recall was issued by the FDA Drug on June 12, 2024. Severity: Moderate. Recall number: D-0533-2024.